Scholar Rock Holding (SRRK) Total Non-Current Liabilities (2017 - 2021)
Scholar Rock Holding (SRRK) posted quarterly Total Non-Current Liabilities of $115.4 million for Q2 2021, down 3.87% quarter-over-quarter from $120.0 million in Q1 2021.
Scholar Rock Holding (SRRK) Total Non-Current Liabilities (2017 - 2021) Analysis & Trends
Scholar Rock Holding's Total Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $115.4 million for Q2 2021.
- In Q2 2021, Total Non-Current Liabilities changed N/A year-over-year to $115.4 million; the TTM figure through Jun 2021 stood at $115.4 million (changed N/A YoY), while the FY2020 annual figure was $127.5 million, up 52.78% from the prior year.
- Total Non-Current Liabilities for Q2 2021 stood at $115.4 million, down from $120.0 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $127.5 million in Q4 2020, with the low at $5.9 million in Q4 2017.
- The 4-year median for Total Non-Current Liabilities is $115.4 million (2021), against an average of $90.5 million.
- Peak annual rise in Total Non-Current Liabilities reached 52.78% in 2020, while the deepest fall reached 52.78% in 2020.
- Scholar Rock Holding's Total Non-Current Liabilities stood at $5.9 million in 2017, then surged by 1317.16% to $83.5 million in 2019, then soared by 52.78% to $127.5 million in 2020, then declined by 9.52% to $115.4 million in 2021.
- Business Quant data shows SRRK's Total Non-Current Liabilities at $115.4 million in Q2 2021, $120.0 million in Q1 2021, and $127.5 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Scholar Rock Holding | 6.39 Bn | 6.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 115.39 Mn |
| Mar 31, 2021 | 120.04 Mn |
| Dec 31, 2020 | 127.53 Mn |
| Dec 31, 2019 | 83.47 Mn |
| Dec 31, 2017 | 5.89 Mn |